News
-
Surveys
Sickle Cell Disease Patients’ Views on Oxbryta
OXBRYTA (voxelotor) is a prescription medicine used for the treatment of sickle cell disease (SCD) and constitutes the first aproved…
Read More » -
NOVITÀ
TIF’s Submission To The UK NICE’s Consultation Document For Zynteglo®
On February 12, in an appraisal consultation document, the UK National Institute for Health and Care Excellence (NICE) recommended against the use…
Read More » -
Member News
Time To Get Ready For Rare Disease Day 2021!
TIF joins forces with 300 million people around the world for the global observance of Rare Disease Day, coming up…
Read More » -
Clinical News
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird…
Read More » -
NOVITÀ
-
NOVITÀ
NOW PUBLISHED: The TIF ‘’Gene Therapy & Thalassaemia’’ Survey Report
Gene therapy for thalassaemia is an expensive and complex procedure, with great efforts ongoing currently by all involved stakeholders, such…
Read More » -
NOVITÀ
TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required
Access to quality-assured medical products improves health and saves lives. Nevertheless, one third of the world’s population lacks timely access…
Read More » -
Member News
TIF Supports IAPO´s Call For The Ratification Of The African Medicines Agency Treaty
Two years after the Treaty to establish an African Medicines Agency was agreed, over 40 leading organizations, including the Thalassaemia…
Read More » -
Clinical News
The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage…
Read More »